Abstract: The present invention is directed to a process for the preparation of cortexolone 17?-propionate, comprising a hydrolysis reaction of an ortho-ester of formula (III) in which R is a hydrogen atom or a methyl group, in the presence of a dilute solution of acetic acid. The present invention is also directed to a hydrated crystalline form of cortexolone 17?-propionate obtained by such process.

Abstract: The present invention is directed to a process for the preparation of cortexolone 17?-propionate, comprising a hydrolysis reaction of an ortho-ester of formula (III) in which R is a hydrogen atom or a methyl group, in the presence of a dilute solution of acetic acid. The present invention is also directed to a hydrated crystalline form of cortexolone 17?-propionate obtained by such process.

Abstract: The present invention is directed to a process for the preparation of cortexolone 17?-propionate, comprising a hydrolysis reaction of an ortho-ester of formula (III) in which R is a hydrogen atom or a methyl group, in the presence of a dilute solution of acetic acid. The present invention is also directed to a hydrated crystalline form of cortexolone 17?-propionate obtained by such process.

Abstract: The present invention relates to a process for the preparation of Fulvestrant which includes recovering the by-products deriving from the oxidation of the corresponding sulfide and then subjecting the by-products to a reduction reaction in the presence of specific reducing agents.

Abstract: The present invention discloses a method for the purification of cysteamine or a salt thereof from polysulfuric impurities, in particular from cystamine, by treatment with dithiothreitol.

Abstract: Provided are intermediates useful for the preparation of verapamil and methods for their preparation.

Abstract: The present invention encompasses processes for preparing drospirenone and intermediates thereof.

Abstract: The present invention provides lyophilized and stable lyophilized anthracycline glycoside salts, in particular, the hydrochloride salt. Also, the present invention provides methods of stabilizing these anthracycline glycoside salts, and methods for producing stable lyophilized anthracycline glycoside salts, such as for example the antineoplastic compound idarubicin hydrochloride, or the compounds doxorubicin hydrochloride, and epirubicin hydrochloride.

Abstract: The present invention provides a new method of producing high quality idarubicin aglycone from 4-protected demethoxydaunomycinones such as 4-demethoxydaunomycinone-4-triflate.

Abstract: The present invention relates to a process for preparing N-methyl-3-(p-trifluoromethylphenoxy)-3-phenyl-propylamine and pharmaceutically acceptable acid addition salts thereof. The process in accordance with the present invention comprises reacting 1-phenyl-3-(N-methylamine) propane-1-ol with 1-chloro-4-trifluoromethylbenzene, in the presence of an hydroxide of an alkaline metal in a dipolar aprotic solvent non saponifiable in reaction conditions. The process in accordance with the present invention further comprises a final crystallization step which allows to obtain the active ingredient in a highly pure crystalline form.

Abstract: A process is described for the preparation of taurocholanic acids of formula (I): ##STR1## in which A completes the 5.beta.-cyclopentaneperhydrophenanthrene structure of a cholanic acid and E is hydrogen or a methyl group, by reacting the corresponding cholanic acid with the chloride of an acid having a tertiary carbon in the alpha-position, and treating the resulting mixed anhydride with taurine.

Abstract: The present invention relates to intermediates for use in the preparation of taurocholanic acids. The intermediates have the following formula (IV): ##STR1## in which A completes the 5.beta.-cyclopentaneperhydrophenanthrene structure of a cholanic acid; E is hydrogen or a methyl; and R is a hydrocarbon residue bonded to the carbonyl group by a tertiary carbon.